<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nodgo</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал детской гематологии и онкологии (РЖДГиО)</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Pediatric Hematology and Oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-1267</issn><issn pub-type="epub">2413-5496</issn><publisher><publisher-name>LTD “Graphica”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21682/2311-1267-2024-11-2-61-66</article-id><article-id custom-type="elpub" pub-id-type="custom">nodgo-1040</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LITERATURE REVIEWS</subject></subj-group></article-categories><title-group><article-title>Роль тромбоцитов в гематогенном метастазировании опухолей</article-title><trans-title-group xml:lang="en"><trans-title>Role of platelets in hematogenous metastasis of tumors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8088-1749</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Краличкин</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kralichkin</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павел Викторович Краличкин: врач-детский онколог стационара кратковременного лечения</p><p>117997, Москва, ул. Саморы Машела, 1</p></bio><bio xml:lang="en"><p>Pediatric Oncologist of the Hospital for Short-Term Treatment</p><p>1 Samory Mashela St., Moscow, 117997</p></bio><email xlink:type="simple">pavel.kralichkin@fccho-moscow.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3704-8783</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Качанов</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kachanov</surname><given-names>D.  Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., заместитель директора Института онкологии, радиологии и ядерной медицины и заведующий отделением клинической онкологии</p><p>117997, Москва, ул. Саморы Машела, 1</p></bio><bio xml:lang="en"><p>Dr. of Sci. (Med.), Deputy Director of the Institute of Oncology, Radiology and Nuclear Medicine &amp; Head of the Department of Clinical Oncology</p><p>1 Samory Mashela St., Moscow, 117997</p></bio><email xlink:type="simple">Denis.Kachanov@fccho-moscow.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2057-2036</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пшонкин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pshonkin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., врач-гематолог, врач-детский онколог, заведующий стационаром кратковременного лечения</p><p>117997, Москва, ул. Саморы Машела, 1</p></bio><bio xml:lang="en"><p>Cand. of Sci. (Med.), Hematologist, Pediatric Oncologist, Head of the Hospital for Short-Term Treatment</p><p>1 Samory Mashela St., Moscow, 117997</p></bio><email xlink:type="simple">alexey.pshonkin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4384-6754</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жарков</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zharkov</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., врач-педиатр, врач-гематолог консультативного отделения, заведующий отделом патологии гемостаза</p><p>Web of Science ResearcherID: AAP-9203-2020</p><p>117997, Москва, ул. Саморы Машела, 1</p></bio><bio xml:lang="en"><p>Dr. of Sci. (Med.), Pediatrician, Hematologist Outpatient Consultative Unit, Head of the Hemostasis Pathology Department</p><p>Web of Science ResearcherID: AAP-9203-2020</p><p>1 Samory Mashela St., Moscow, 117997</p></bio><email xlink:type="simple">pavel.zharkov@fccho-moscow.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>12</day><month>08</month><year>2024</year></pub-date><volume>11</volume><issue>2</issue><fpage>61</fpage><lpage>66</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Краличкин П.В., Качанов Д.Ю., Пшонкин А.В., Жарков П.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Краличкин П.В., Качанов Д.Ю., Пшонкин А.В., Жарков П.А.</copyright-holder><copyright-holder xml:lang="en">Kralichkin P.V., Kachanov D.Y., Pshonkin A.V., Zharkov P.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nodgo.org/jour/article/view/1040">https://journal.nodgo.org/jour/article/view/1040</self-uri><abstract><p>Общеизвестными функциями тромбоцитов являются участие в системе гемостаза и тромбообразование, которые в свою очередь исполняются путем их адгезии к поврежденным тканям, а также агрегации между собой с образованием гемостатической пробки, перекрывающей повреждение. Способности к адгезии и агрегации тромбоцитов определяются их специфическими мембранными гликопротеинами.</p><p>Однако функционал тромбоцитов не ограничивается исключительно тромбообразованием. К примеру, имеются данные об использовании опухолевыми клетками тромбоцитов для осуществления метастазирования. Настоящая публикация обобщает международную литературу, посвященную роли тромбоцитов в гематогенном метастазировании опухолей.</p></abstract><trans-abstract xml:lang="en"><p>The well-known functions of platelets are participation in the hemostasis system and thrombosis, which, in turn, are performed by their adhesion to damaged tissues, as well as aggregation among themselves with the formation of a hemostatic plug that covers the lesion. The adhesion and aggregation abilities of platelets are determined by their specific membrane glycoproteins.</p><p>However, platelet functionality is not limited solely to thrombosis. For example, there is evidence for the use of platelets by tumor cells to effect metastasis. This publication summarizes the international literature on the role of platelets in hematogenous tumor metastasis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тромбоциты</kwd><kwd>гемостаз</kwd><kwd>метастазирование</kwd><kwd>пролиферация</kwd><kwd>ангиогенез</kwd></kwd-group><kwd-group xml:lang="en"><kwd>platelets</kwd><kwd>hemostasis</kwd><kwd>metastasis</kwd><kwd>proliferation</kwd><kwd>angiogenesis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено без спонсорской поддержки.</funding-statement><funding-statement xml:lang="en">The study was performed without external funding.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lefrancais E., Ortiz-Munoz G., Caudrillier A., Mallavia B., Liu F., Sayah D.M. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105–9. doi:10.1038/nature21706.</mixed-citation><mixed-citation xml:lang="en">Lefrancais E., Ortiz-Munoz G., Caudrillier A., Mallavia B., Liu F., Sayah D.M. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105–9. doi:10.1038/nature21706.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Holinstat M. Normal platelet function. Cancer Metastasis Rev. 2017;36:195–8. doi: 10.1007/s10555-017-9677-x.</mixed-citation><mixed-citation xml:lang="en">Holinstat M. Normal platelet function. Cancer Metastasis Rev. 2017;36:195–8. doi: 10.1007/s10555-017-9677-x.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Holinstat M., Tourdot B.E. Coronary heart disease risk factors take a disproportional toll on women. Arterioscler Thromb Vasc Biol. 2015;35(4):750–1. doi:10.1161/ATVBAHA.115.305466.</mixed-citation><mixed-citation xml:lang="en">Holinstat M., Tourdot B.E. Coronary heart disease risk factors take a disproportional toll on women. Arterioscler Thromb Vasc Biol. 2015;35(4):750–1. doi:10.1161/ATVBAHA.115.305466.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Koupenova M., Mick E., Mikhalev E., Benjamin E.J., Tanriverdi K., Freedman J.E. Sex diff erences in platelet toll-like receptors and their association with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2015;35(4):1030–7. doi: 10.1161/ATVBAHA.114.304954.</mixed-citation><mixed-citation xml:lang="en">Koupenova M., Mick E., Mikhalev E., Benjamin E.J., Tanriverdi K., Freedman J.E. Sex diff erences in platelet toll-like receptors and their association with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2015;35(4):1030–7. doi: 10.1161/ATVBAHA.114.304954.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Clemetson K.J. Platelets and pathogens. Cell Mol Life Sci. 2010;67(4):495–8. doi: 10.1007/s00018-009-0204-2.</mixed-citation><mixed-citation xml:lang="en">Clemetson K.J. Platelets and pathogens. Cell Mol Life Sci. 2010;67(4):495–8. doi: 10.1007/s00018-009-0204-2.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Stark R.J., Aghakasiri N., Rumbaut R.E. Platelet-derived Toll-like receptor 4 (Tlr-4) is suffi cient to promote microvascular thrombosis in endotoxemia. PLoS One. 2012;7(7):e41254. doi: 10.1371/journal.pone.0041254.</mixed-citation><mixed-citation xml:lang="en">Stark R.J., Aghakasiri N., Rumbaut R.E. Platelet-derived Toll-like receptor 4 (Tlr-4) is suffi cient to promote microvascular thrombosis in endotoxemia. PLoS One. 2012;7(7):e41254. doi: 10.1371/journal.pone.0041254.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cox D., Kerrigan S.W., Watson S.P. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost. 2011;9(6):1097–107. doi: 10.1111/j.1538-7836.2011.04264.x.</mixed-citation><mixed-citation xml:lang="en">Cox D., Kerrigan S.W., Watson S.P. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost. 2011;9(6):1097–107. doi: 10.1111/j.1538-7836.2011.04264.x.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Elgueta R., Benson M.J., de Vries V.C., Wasiuk A., Guo Y., Noelle R.J. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152–72. doi: 10.1111/j.1600-065X.2009.00782.x.</mixed-citation><mixed-citation xml:lang="en">Elgueta R., Benson M.J., de Vries V.C., Wasiuk A., Guo Y., Noelle R.J. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152–72. doi: 10.1111/j.1600-065X.2009.00782.x.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Danese S., Katz J.A., Saibeni S., Papa A., Gasbarrini A., Vecchi M., Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of infl ammatory bowel disease patients. Gut. 2003;52(10):1435–41. doi: 10.1136/gut.52.10.1435.</mixed-citation><mixed-citation xml:lang="en">Danese S., Katz J.A., Saibeni S., Papa A., Gasbarrini A., Vecchi M., Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of infl ammatory bowel disease patients. Gut. 2003;52(10):1435–41. doi: 10.1136/gut.52.10.1435.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yacoub D., Hachem A., Théorêt J.F., Gillis M.A., Mourad W., Merhi Y. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol. 2010;30(12):2424–33. doi: 10.1161/ATVBAHA.110.216143.</mixed-citation><mixed-citation xml:lang="en">Yacoub D., Hachem A., Théorêt J.F., Gillis M.A., Mourad W., Merhi Y. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol. 2010;30(12):2424–33. doi: 10.1161/ATVBAHA.110.216143.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Semple J.W., Italiano J.E. Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264–74. doi: 10.1038/nri2956.</mixed-citation><mixed-citation xml:lang="en">Semple J.W., Italiano J.E. Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264–74. doi: 10.1038/nri2956.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Youssefi an T., Drouin A., Massé J.M., Guichard J., Cramer E.M. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specifi c subcellular compartment and is enhanced by platelet activation. Blood. 2002;99(11):4021–9. doi: 10.1182/blood-2001-12-0191.</mixed-citation><mixed-citation xml:lang="en">Youssefi an T., Drouin A., Massé J.M., Guichard J., Cramer E.M. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specifi c subcellular compartment and is enhanced by platelet activation. Blood. 2002;99(11):4021–9. doi: 10.1182/blood-2001-12-0191.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Maouia A., Rebetz J., Kapur R., Semple J.W. The Immune Nature of Platelets Revisited. Transfus Med Rev. 2020;34(4):209–20. doi: 10.1016/j.tmrv.2020.09.005.</mixed-citation><mixed-citation xml:lang="en">Maouia A., Rebetz J., Kapur R., Semple J.W. The Immune Nature of Platelets Revisited. Transfus Med Rev. 2020;34(4):209–20. doi: 10.1016/j.tmrv.2020.09.005.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wong C.H., Jenne C.N., Petri B., Chrobok N.L., Kubes P. Nucleation of platelets with blood-borne pathogens on Kupff er cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol. 2013;14(8):785–92. doi: 10.1038/ni.2631.</mixed-citation><mixed-citation xml:lang="en">Wong C.H., Jenne C.N., Petri B., Chrobok N.L., Kubes P. Nucleation of platelets with blood-borne pathogens on Kupff er cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol. 2013;14(8):785–92. doi: 10.1038/ni.2631.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mishan M.A., Ahmadiankia N., Bahrami A.R. CXCR4 and CCR7: Two eligible targets in targeted cancer therapy. Cell Biol Int. 2016;40(9):955–67. doi: 10.1002/cbin.10631.</mixed-citation><mixed-citation xml:lang="en">Mishan M.A., Ahmadiankia N., Bahrami A.R. CXCR4 and CCR7: Two eligible targets in targeted cancer therapy. Cell Biol Int. 2016;40(9):955–67. doi: 10.1002/cbin.10631.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Seyfried T.N., Huysentruyt L.C. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1–2):43–73. doi: 10.1615/critrevoncog.v18.i1-2.40.</mixed-citation><mixed-citation xml:lang="en">Seyfried T.N., Huysentruyt L.C. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1–2):43–73. doi: 10.1615/critrevoncog.v18.i1-2.40.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–34. doi: 10.1038/nrc3004.</mixed-citation><mixed-citation xml:lang="en">Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–34. doi: 10.1038/nrc3004.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Elaskalani O., Berndt M.C., Falasca M., Metharom P. Targeting Platelets for the Treatment of Cancer. Cancers (Basel). 2017;9(7):94. doi: 10.3390/cancers9070094.</mixed-citation><mixed-citation xml:lang="en">Elaskalani O., Berndt M.C., Falasca M., Metharom P. Targeting Platelets for the Treatment of Cancer. Cancers (Basel). 2017;9(7):94. doi: 10.3390/cancers9070094.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Melki I., Tessandier N., Zuff erey A., Boilard E. Platelet microvesicles in health and disease. Platelets. 2017;28(3):214–21. doi: 10.1080/09537104.2016.1265924.</mixed-citation><mixed-citation xml:lang="en">Melki I., Tessandier N., Zuff erey A., Boilard E. Platelet microvesicles in health and disease. Platelets. 2017;28(3):214–21. doi: 10.1080/09537104.2016.1265924.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Naderi-Meshkin H., Ahmadiankia N. Cancer metastasis versus stem cell homing: Role of platelets. J Cell Physiol. 2018;233(12):9167–78. doi: 10.1002/jcp.26937.</mixed-citation><mixed-citation xml:lang="en">Naderi-Meshkin H., Ahmadiankia N. Cancer metastasis versus stem cell homing: Role of platelets. J Cell Physiol. 2018;233(12):9167–78. doi: 10.1002/jcp.26937.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Reneman R.S., Hoeks A.P. Wall shear stress as measured in vivo: consequences for the design of the arterial system. Med Biol Eng Comput. 2008;46(5):499–507. doi: 10.1007/s11517-008-0330-2.</mixed-citation><mixed-citation xml:lang="en">Reneman R.S., Hoeks A.P. Wall shear stress as measured in vivo: consequences for the design of the arterial system. Med Biol Eng Comput. 2008;46(5):499–507. doi: 10.1007/s11517-008-0330-2.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Erpenbeck L., Schön M.P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115(17):3427–36. doi: 10.1182/blood-2009-10-247296.</mixed-citation><mixed-citation xml:lang="en">Erpenbeck L., Schön M.P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115(17):3427–36. doi: 10.1182/blood-2009-10-247296.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gay L.J., Felding-Habermann B. Platelets alter tumor cell attributes to propel metastasis: programming in transit. Cancer Cell. 2011;20(5):553–4. doi: 10.1016/j.ccr.2011.11.001.</mixed-citation><mixed-citation xml:lang="en">Gay L.J., Felding-Habermann B. Platelets alter tumor cell attributes to propel metastasis: programming in transit. Cancer Cell. 2011;20(5):553–4. doi: 10.1016/j.ccr.2011.11.001.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kitamura T., Qian B.Z., Pollard J.W. Immune cell promotion of metastasis. Nat Rev Immunol. 2015;15(2):73–86. doi: 10.1038/nri3789.</mixed-citation><mixed-citation xml:lang="en">Kitamura T., Qian B.Z., Pollard J.W. Immune cell promotion of metastasis. Nat Rev Immunol. 2015;15(2):73–86. doi: 10.1038/nri3789.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Palumbo J.S., Degen J.L. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 2007;120 Suppl 2: S22–8. doi: 10.1016/S0049-3848(07)70127-5.</mixed-citation><mixed-citation xml:lang="en">Palumbo J.S., Degen J.L. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 2007;120 Suppl 2: S22–8. doi: 10.1016/S0049-3848(07)70127-5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008;8(8):1247–55. doi: 10.1586/14737140.8.8.1247.</mixed-citation><mixed-citation xml:lang="en">Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008;8(8):1247–55. doi: 10.1586/14737140.8.8.1247.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Placke T., Örgel M., Schaller M., Jung G., Rammensee H.G., Kopp H.G., Salih H.R. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8. doi: 10.1158/0008-5472.CAN-11-1872.</mixed-citation><mixed-citation xml:lang="en">Placke T., Örgel M., Schaller M., Jung G., Rammensee H.G., Kopp H.G., Salih H.R. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8. doi: 10.1158/0008-5472.CAN-11-1872.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., Carbone D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically aff ects the diff erentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150–66. PMID: 9834220.</mixed-citation><mixed-citation xml:lang="en">Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., Carbone D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically aff ects the diff erentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150–66. PMID: 9834220.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Laxmanan S., Robertson S.W., Wang E., Lau J.S., Briscoe D.M., Mukhopadhyay D. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun. 2005;334(1):193–8. doi: 10.1016/j.bbrc.2005.06.065.</mixed-citation><mixed-citation xml:lang="en">Laxmanan S., Robertson S.W., Wang E., Lau J.S., Briscoe D.M., Mukhopadhyay D. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun. 2005;334(1):193–8. doi: 10.1016/j.bbrc.2005.06.065.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Reddig P.J., Juliano R.L. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev. 2005;24(3):425–39. doi: 10.1007/s10555-005-5134-3.</mixed-citation><mixed-citation xml:lang="en">Reddig P.J., Juliano R.L. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev. 2005;24(3):425–39. doi: 10.1007/s10555-005-5134-3.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Alfano D., Iaccarino I., Stoppelli M.P. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem. 2006;281(26):17758–67. doi: 10.1074/jbc.M601812200.</mixed-citation><mixed-citation xml:lang="en">Alfano D., Iaccarino I., Stoppelli M.P. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem. 2006;281(26):17758–67. doi: 10.1074/jbc.M601812200.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E., Peeper D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430(7003):1034–9. doi: 10.1038/nature02765.</mixed-citation><mixed-citation xml:lang="en">Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E., Peeper D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430(7003):1034–9. doi: 10.1038/nature02765.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Golebiewska E.M., Poole A.W. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153–62. doi: 10.1016/j.blre.2014.10.003.</mixed-citation><mixed-citation xml:lang="en">Golebiewska E.M., Poole A.W. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153–62. doi: 10.1016/j.blre.2014.10.003.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81. doi: 10.1038/nrc2088.</mixed-citation><mixed-citation xml:lang="en">Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81. doi: 10.1038/nrc2088.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Tanaka K., Okugawa Y., Toiyama Y., Inoue Y., Saigusa S., Kawamura M., Araki T., Uchida K., Mohri Y., Kusunoki M. Brainderived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. PLoS One. 2014;9(5):e96410. doi: 10.1371/journal.pone.0096410.</mixed-citation><mixed-citation xml:lang="en">Tanaka K., Okugawa Y., Toiyama Y., Inoue Y., Saigusa S., Kawamura M., Araki T., Uchida K., Mohri Y., Kusunoki M. Brainderived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. PLoS One. 2014;9(5):e96410. doi: 10.1371/journal.pone.0096410.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao Y.C., Yang Z.B., Cheng X.S., Fang X.B., Shen T., Xia C.F., Liu P., Qian H.H., Sun B., Yin Z.F., Li Y.F. CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. Cancer Lett. 2015;361(1):22–32. doi: 10.1016/j.canlet.2015.02.021.</mixed-citation><mixed-citation xml:lang="en">Xiao Y.C., Yang Z.B., Cheng X.S., Fang X.B., Shen T., Xia C.F., Liu P., Qian H.H., Sun B., Yin Z.F., Li Y.F. CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. Cancer Lett. 2015;361(1):22–32. doi: 10.1016/j.canlet.2015.02.021.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng Q., McCauley L.K., Wang C.Y. Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem. 2002;277(51):50137–42. doi: 10.1074/jbc.M208952200.</mixed-citation><mixed-citation xml:lang="en">Zeng Q., McCauley L.K., Wang C.Y. Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem. 2002;277(51):50137–42. doi: 10.1074/jbc.M208952200.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Luey B.C., May F.E. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer. 2016;15:8. doi: 10.1186/s12943-015-0482-2.</mixed-citation><mixed-citation xml:lang="en">Luey B.C., May F.E. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer. 2016;15:8. doi: 10.1186/s12943-015-0482-2.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100(2):350–6. doi: 10.1172/JCI119540.</mixed-citation><mixed-citation xml:lang="en">Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100(2):350–6. doi: 10.1172/JCI119540.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Chanvorachote P., Pongrakhananon V., Chunhacha P. Prolonged nitric oxide exposure enhances anoikis resistance and migration through epithelial-mesenchymal transition and caveolin-1 upregulation. Biomed Res Int. 2014;2014:941359. doi: 10.1155/2014/941359.</mixed-citation><mixed-citation xml:lang="en">Chanvorachote P., Pongrakhananon V., Chunhacha P. Prolonged nitric oxide exposure enhances anoikis resistance and migration through epithelial-mesenchymal transition and caveolin-1 upregulation. Biomed Res Int. 2014;2014:941359. doi: 10.1155/2014/941359.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Bao W., Qiu H., Yang T., Luo X., Zhang H., Wan X. Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One. 2013;8(7):e70616. doi: 10.1371/journal.pone.0070616.</mixed-citation><mixed-citation xml:lang="en">Bao W., Qiu H., Yang T., Luo X., Zhang H., Wan X. Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One. 2013;8(7):e70616. doi: 10.1371/journal.pone.0070616.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Jie X.X., Zhang X.Y., Xu C.J. Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications. Oncotarget. 2017;8(46):81558–71. doi: 10.18632/oncotarget.18277.</mixed-citation><mixed-citation xml:lang="en">Jie X.X., Zhang X.Y., Xu C.J. Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications. Oncotarget. 2017;8(46):81558–71. doi: 10.18632/oncotarget.18277.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Moustakas A., Heldin C.H. Signaling networks guiding epithelialmesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98(10):1512–20. doi: 10.1111/j.1349-7006.2007.00550.x.</mixed-citation><mixed-citation xml:lang="en">Moustakas A., Heldin C.H. Signaling networks guiding epithelialmesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98(10):1512–20. doi: 10.1111/j.1349-7006.2007.00550.x.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Palena C., Hamilton D.H., Fernando R.I. Infl uence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012;8(6):713–22. doi: 10.2217/fon.12.59.</mixed-citation><mixed-citation xml:lang="en">Palena C., Hamilton D.H., Fernando R.I. Infl uence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012;8(6):713–22. doi: 10.2217/fon.12.59.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Li N. Platelets in cancer metastasis: To help the “villain” to do evil. Int J Cancer. 2016;138(9):2078–87. doi: 10.1002/ijc.29847.</mixed-citation><mixed-citation xml:lang="en">Li N. Platelets in cancer metastasis: To help the “villain” to do evil. Int J Cancer. 2016;138(9):2078–87. doi: 10.1002/ijc.29847.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">McCarty O.J., Mousa S.A., Bray P.F., Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and fi rm adhesion under dynamic fl ow conditions. Blood. 2000;96(5):1789–97. PMID: 10961878.</mixed-citation><mixed-citation xml:lang="en">McCarty O.J., Mousa S.A., Bray P.F., Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and fi rm adhesion under dynamic fl ow conditions. Blood. 2000;96(5):1789–97. PMID: 10961878.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Janowska-Wieczorek A., Wysoczynski M., Kijowski J., MarquezCurtis L., Machalinski B., Ratajczak J., Ratajczak M.Z. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113(5):752–60. doi: 10.1002/ijc.20657.</mixed-citation><mixed-citation xml:lang="en">Janowska-Wieczorek A., Wysoczynski M., Kijowski J., MarquezCurtis L., Machalinski B., Ratajczak J., Ratajczak M.Z. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113(5):752–60. doi: 10.1002/ijc.20657.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Коваленко Т.А., Пантелеев М.А., Свешникова А.Н. Роль тканевого фактора в метастазировании, неоангиогенезе и гемостазе при онкологических заболеваниях. Онкогематология. 2019;14(2):70–85. doi: 10.17650/1818-8346-2019-14-2-70-85.</mixed-citation><mixed-citation xml:lang="en">Kovalenko T.A., Panteleev M.A., Sveshnikova A.N. The role of tissue factor in metastasising, neoangiogenesis and hemostasis in cancer. Onkogematologiya = Oncohematology. 2019;14(2):70–85. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Бутылин А.А., Пантелеев М.А., Атауллаханов Ф.И. Пространственная динамика свертывания крови. Российский химический журнал. 2007;51(1):45–50.</mixed-citation><mixed-citation xml:lang="en">Butylin A.A., Panteleev M.A., Ataluhanov F.I. Spatial dynamics of blood coagulation. Russian Chemical Journal. 2007;51(1):45–50. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Подоплелова Н.А., Сулимов В.Б., Тащилова А.С., Ильин И.С., Пантелеев М.А., Ледeнева И.В., Шихалиев Х.С. Свертывание крови в XXI веке: новые знания, методы и перспективы для терапии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(1):139–57. doi: 10.24287/1726-1708-2020-19-1-139-157.</mixed-citation><mixed-citation xml:lang="en">Podoplelova N.A., Sulimov V.B., Ilin I.S., Tashilova A.S., Panteleev M.A., Ledeneva I.V., Shikhaliev Kh.S. Blood coagulation in the 21st century: existing knowledge, current strategies for treatment and perspective. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2020;19(1):139–57. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Fischer E.G., Riewald M., Huang H.Y., Miyagi Y., Kubota Y., Mueller B.M., Ruf W. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest. 1999;104(9):1213–21. doi: 10.1172/JCI7750.</mixed-citation><mixed-citation xml:lang="en">Fischer E.G., Riewald M., Huang H.Y., Miyagi Y., Kubota Y., Mueller B.M., Ruf W. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest. 1999;104(9):1213–21. doi: 10.1172/JCI7750.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Orellana R., Kato S., Erices R., Bravo M.L., Gonzalez P., Oliva B., Cubillos S., Valdivia A., Ibañez C., Brañes J., Barriga M.I., Bravo E., Alonso C., Bustamente E., Castellon E., Hidalgo P., Trigo C., Panes O., Pereira J., Mezzano D., Cuello M.A., Owen G.I. Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer. 2015;15:290. doi: 10.1186/s12885-015-1304-z.</mixed-citation><mixed-citation xml:lang="en">Orellana R., Kato S., Erices R., Bravo M.L., Gonzalez P., Oliva B., Cubillos S., Valdivia A., Ibañez C., Brañes J., Barriga M.I., Bravo E., Alonso C., Bustamente E., Castellon E., Hidalgo P., Trigo C., Panes O., Pereira J., Mezzano D., Cuello M.A., Owen G.I. Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer. 2015;15:290. doi: 10.1186/s12885-015-1304-z.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Läubli H., Spanaus K.S., Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009;114(20):4583–91. doi: 10.1182/blood-2008-10-186585.</mixed-citation><mixed-citation xml:lang="en">Läubli H., Spanaus K.S., Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009;114(20):4583–91. doi: 10.1182/blood-2008-10-186585.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90. doi: 10.1016/j.ccr.2011.09.009.</mixed-citation><mixed-citation xml:lang="en">Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90. doi: 10.1016/j.ccr.2011.09.009.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Padua D., Zhang X.H., Wang Q., Nadal C., Gerald W.L., Gomis R.R., Massagué J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77. doi: 10.1016/j.cell.2008.01.046.</mixed-citation><mixed-citation xml:lang="en">Padua D., Zhang X.H., Wang Q., Nadal C., Gerald W.L., Gomis R.R., Massagué J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77. doi: 10.1016/j.cell.2008.01.046.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Bielenberg D.R., Zetter B.R. The Contribution of Angiogenesis to the Process of Metastasis. Cancer J. 2015;21(4):267–73. doi: 10.1097/PPO.0000000000000138.</mixed-citation><mixed-citation xml:lang="en">Bielenberg D.R., Zetter B.R. The Contribution of Angiogenesis to the Process of Metastasis. Cancer J. 2015;21(4):267–73. doi: 10.1097/PPO.0000000000000138.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Wojtukiewicz M.Z., Sierko E., Hempel D., Tucker S.C., Honn K.V. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249–62. doi: 10.1007/s10555-017-9673-1.</mixed-citation><mixed-citation xml:lang="en">Wojtukiewicz M.Z., Sierko E., Hempel D., Tucker S.C., Honn K.V. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249–62. doi: 10.1007/s10555-017-9673-1.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">He A.D., Xie W., Song W., Ma Y.Y., Liu G., Liang M.L., Da X.W., Yao G.Q., Zhang B.X., Gao C.J., Xiang J.Z., Ming Z.Y. Platelet releasates promote the proliferation of hepatocellular carcinoma cells by suppressing the expression of KLF6. Sci Rep. 2017;7(1):3989. doi: 10.1038/s41598-017-02801-1.</mixed-citation><mixed-citation xml:lang="en">He A.D., Xie W., Song W., Ma Y.Y., Liu G., Liang M.L., Da X.W., Yao G.Q., Zhang B.X., Gao C.J., Xiang J.Z., Ming Z.Y. Platelet releasates promote the proliferation of hepatocellular carcinoma cells by suppressing the expression of KLF6. Sci Rep. 2017;7(1):3989. doi: 10.1038/s41598-017-02801-1.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Banskota S., Gautam J., Regmi S.C., Gurung P., Park M.H., Kim S.J., Nam T.G., Jeong B.S., Kim J.A. BJ-1108, a 6-Amino-2,4,5- Trimethylpyridin-3-ol Analog, Inhibits Serotonin-Induced Angiogenesis and Tumor Growth through PI3K/NOX. Pathway. PLoS One. 2016;11(1):e0148133. doi: 10.1371/journal.pone.0148133.</mixed-citation><mixed-citation xml:lang="en">Banskota S., Gautam J., Regmi S.C., Gurung P., Park M.H., Kim S.J., Nam T.G., Jeong B.S., Kim J.A. BJ-1108, a 6-Amino-2,4,5- Trimethylpyridin-3-ol Analog, Inhibits Serotonin-Induced Angiogenesis and Tumor Growth through PI3K/NOX. Pathway. PLoS One. 2016;11(1):e0148133. doi: 10.1371/journal.pone.0148133.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Wang S., Li Z., Xu R. Human Cancer and Platelet Interaction, a Potential Therapeutic Target. Int J Mol Sci. 2018;19(4):1246. doi: 10.3390/ijms19041246.</mixed-citation><mixed-citation xml:lang="en">Wang S., Li Z., Xu R. Human Cancer and Platelet Interaction, a Potential Therapeutic Target. Int J Mol Sci. 2018;19(4):1246. doi: 10.3390/ijms19041246.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
